Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer | Zendy

David R. Spigel | Zendy; Thomas J. Ervin | Zendy; Rodryg Ramlau | Zendy; Davey B. Daniel | Zendy; Jerome H. Goldschmidt | Zendy; George R. Blumenschein | Zendy; Maciej Krzakowski | Zendy; G. Robinet | Zendy; B. Godbert | Zendy; Fabrice Barlési | Zendy; Ramaswamy Govindan | Zendy; Taral Patel | Zendy; С. В. Орлов | Zendy; M. S. Wertheim | Zendy; Wei Yu | Zendy; Jiping Zha | Zendy; Robert L. Yauch | Zendy; Premal H. Patel | Zendy; S. Phan | Zendy; Amy Peterson | Zendy

Open Access

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Author(s) -

David R. Spigel,

Thomas J. Ervin,

Rodryg Ramlau,

Davey B. Daniel,

Jerome H. Goldschmidt,

George R. Blumenschein,

Maciej Krzakowski,

G. Robinet,

B. Godbert,

Fabrice Barlési,

Ramaswamy Govindan,

Taral Patel,

С. В. Орлов,

M. S. Wertheim,

Wei Yu,

Jiping Zha,

Robert L. Yauch,

Premal H. Patel,

S. Phan,

Amy Peterson

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.47.4189

Subject(s) - medicine , erlotinib , lung cancer , randomized controlled trial , oncology , cancer , epidermal growth factor receptor

Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) -targeted drugs in patients with non-small-cell lung cancer (NSCLC). We investigated whether dual inhibition of MET/EGFR results in clinical benefit in patients with NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research